Equillium, Inc. (NASDAQ:EQ) Short Interest Update

Key Points

• Equillium, Inc. experienced a significant decline in short interest of 37.5% in August, dropping to 2,050,000 shares as of August 31st.
• The company's stock has a consensus rating of "Hold" from analysts, with an average price target of $1.00.
• Equillium's stock fell by 8.6% during recent trading, with a current price of $1.71, down from a one-year high of $2.35.

Equillium, Inc. (NASDAQ:EQ - Get Free Report) was the recipient of a significant decline in short interest in August. As of August 31st, there was short interest totaling 2,050,000 shares, a decline of 37.5% from the August 15th total of 3,280,000 shares. Based on an average daily volume of 8,230,000 shares, the short-interest ratio is presently 0.2 days. Currently, 5.0% of the shares of the stock are sold short. Currently, 5.0% of the shares of the stock are sold short. Based on an average daily volume of 8,230,000 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Equillium to a "sell" rating in a research note on Friday, September 5th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $1.00.

Equillium Stock Down 8.6%

NASDAQ:EQ traded down $0.16 during trading hours on Monday, hitting $1.71. 877,029 shares of the company's stock traded hands, compared to its average volume of 2,805,526. Equillium has a twelve month low of $0.27 and a twelve month high of $2.35. The stock's fifty day moving average price is $1.01 and its two-hundred day moving average price is $0.66.

Equillium (NASDAQ:EQ - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equillium had a negative net margin of 19.62% and a negative return on equity of 139.56%. On average, sell-side analysts forecast that Equillium will post 0.14 earnings per share for the current fiscal year.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.